Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report

Abstract

Abstract. Extraskeletal osteosarcomas (EOSs) are rare variants of primary osteosarcoma of the bone, and are defined as sarcomas located in the soft tissues and characterized by osteoid production. EOS exhibits distinctive demographic, imaging and prognostic features compared with osteosarcoma of bone origin. The available data are contradictory with regard to the use of chemotherapy regimens in the management of EOS. The present study describes a case of EOS that progressed following two lines of therapy oriented to soft-tissue and bone sarcoma histology, respectively. As a gemcitabine-docetaxel combination schedule has demonstrated synergistic activity against bone and soft-tissue sarcoma histologies, this chemotherapy regimen was selected as salvage therapy. The treatment was well-tolerated and induced a long lasting partial response for ~14 months. To the best of our knowledge, this is the first report involving the clinical use of this combination regimen for the treatment of EOS. Furthermore, as demonstrated in this report, EOS may maintain relative chemosensitivity, indicating the potential to control advanced disease in the long term and to plan subsequent chemotherapy regimens.

Progress in the chemotherapeutic treatment of osteosarcoma (Review)

“…The results of a small-sample phase II clinical trial have indicated that the effective rate of GEM monotherapy is <10%. Recent studies (47,53,56,57) have also indicated that TXT can increase the expression of thymidine phosphorylase in tumor tissue, thereby enhancing the antitumor activity of GEM, resulting in synergistic antitumor effects ranging from 17-30% (58). He et al (51) reported that 80% of patients [median OS duration: 13 months; median progression-free survival (PFS): 6-7 months] receiving GEM in combination with TXT as second-line therapy experienced 12-and 24-month survival rates of 66 and 80%, respectively.…”

Pancreatic Extraskeletal Osteosarcoma Metastasizing to the Scalp

“…ESOSs are characterized by soft-tissue sarcomas that produce osteoid bone and/or cartilage but show no connection to the skeletal system 1 8 9 . There have been few reported cases of ESOS in the literature with only 300 cases reported since it was first described by Wilson in 1941 1 8 .…”

“…ESOSs are characterized by soft-tissue sarcomas that produce osteoid bone and/or cartilage but show no connection to the skeletal system 1 8 9 . There have been few reported cases of ESOS in the literature with only 300 cases reported since it was first described by Wilson in 1941 1 8 . Although the lower extremities and retroperitoneum are common sites, ESOSs have been reported in other organs such as the larynx, esophagus, breast, liver, duodenum, kidney, urinary bladder, orbit, and skin 1 4 5 7 10 .…”

“…It clinically manifests as a painless lesion in the lower extremities, most commonly occurring in the muscles of the thigh followed by the retroperitoneum and upper limb 1 6 7 . The lung is the most common site for the metastasis of ESOS followed by the regional lymph nodes 3 8 . The reported skin metastases from ESOS have been exceedingly rare 1 6 .…”

Primary osteosarcoma of the uterine corpus: A case report

“…Hence, optimal treatment regimens to control this type of disease are desired. In a recent study, a combination of gemcitabine and docetaxel resulted in long‐term response in patients with extraskeletal osteosarcoma . According to the National Comprehensive Cancer Network guidelines for soft tissue sarcoma, docetaxel and gemcitabine are cited as options for non‐specific subtypes of soft tissue sarcoma, including osteosarcoma.…”